Recent Company News

• 04:33 PM ET Sep 16, 2025
  

  Teva to host conference call to discuss data from the completed phase 3 SOLARIS trial for Olanzapine LAI (TEV-'749) on 22-Sep ($18.68, 0.00)

• 04:30 PM ET Sep 16, 2025
  

  Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-'749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

• 09:35 AM ET Sep 16, 2025
  

  FDA publishes dozens of Untitled Letters sent to public biopharma companies

• 04:37 PM ET Sep 15, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:59 PM ET Sep 12, 2025
  

  Alkermes discloses patent infringement lawsuits against Teva, Apotex, and MSN around LYBALVI use - 8-K ($26.97, 0.00)

• 02:07 AM ET Sep 11, 2025
  

  H. Lundbeck announces new clinical migraine data, including long-term preventive effectiveness of Vyepti (eptinezumab) in patients severely impacted by migraine (DKK 41.80, 0.00)

• 03:20 PM ET Sep 10, 2025
  

  MedinCell notes approval of UZEDY in South Korea (€18.67, 0.00)

• 09:14 AM ET Sep 10, 2025
  

  FDA issues new guidance to expand non-opioid options for chronic pain

• 08:31 AM ET Sep 09, 2025
  

  Teva Pharmaceutical's Emrusolmin granted U.S. FDA Fast Track Designation for treatment of Multiple System Atrophy ($19.30, 0.00)

• 08:29 AM ET Sep 09, 2025
  

  Teva's Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy